The Combination Therapy in Breast Cancer Treatment

Abstract

Breast cancer (BC) is the cancer that most commonly diagnosed worldwide, which result in the cause of cancer-related deaths. The majority of BC diagnoses were HR+ and HER2- (71%) and HER2+BC accounts for 10-20% of all breast tumors. There is no magic drug for the treatment of breast cancer at present. Endocrine therapy is the preferable treatment for HR+/HER2- metastatic breast cancer. However, long-term use may produce certain drug resistance. Tucatinib, as a HER2 inhibitor, can be combined with chemotherapy to treat HER2+BC.Combination therapy can offers patients the opportunity to derive the maximum benefit from treatment, at the same time, it can minimize or eliminate relapse, drug resistance and toxic effects and thus the BC patients can have a good quality of life. This paper discussed the combination therapy of endocrine therapy or tucatinib with other drugs and compared their advantages and disadvantages in breast cancer therapy, providing better choice for clinical treatment of BC.